Product Information
METHYLPHENIDATE 5 MG TABLET is a generic product labeled by Solco Healthcare US LLC, priced at $0.1268 per EA under NDC 43547048610. Its NADAC has been published 276 times since Jun 23, 2021.
FDA first approved this application on Jul 23, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547048610
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212697FDA Approved
7/23/2020
TE Code
AB
On Market Since
7/1/2020
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE 5 MG TABLET has been published 276 times since Jun 23, 2021, and over the history we have for it it has risen 19.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1268 per EA |
|---|---|
| All-time high | $0.1434 (Feb 11, 2026) |
| All-time low | $0.0841 (Jul 17, 2024) |
| 52-week high | $0.1434 |
| 52-week low | $0.1268 |
| Median price | $0.1118 |
| Average price | $0.1164 |
| Largest weekly change | +55.5% (Aug 21, 2024) |
| Weeks tracked | 276 |
| Tracking since | Jun 23, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylphenidate hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE 5 MG TABLET, manufactured by Solco Healthcare US LLC, is $0.1268 per EA (NDC 43547048610), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE 5 MG TABLET has risen 19.7%. It has been tracked across 276 weekly CMS publications since Jun 23, 2021.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE 5 MG TABLET?
Since Jun 23, 2021, the NADAC for METHYLPHENIDATE 5 MG TABLET has ranged from a low of $0.0841 (Jul 17, 2024) to a high of $0.1434 (Feb 11, 2026), with a median of $0.1118 per EA.
Are there cheaper alternatives to METHYLPHENIDATE 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of METHYLPHENIDATE 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METHYLPHENIDATE 5 MG TABLET?
METHYLPHENIDATE 5 MG TABLET (NDC 43547048610) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.